Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Beyond BCMA: GPRC5D-directed CAR T-cell therapy is emerging as a promising option for multiple myeloma patients who've exhausted standard treatments. Arlocabtagene autoleucel (arlo-cel) posted an 87% overall response rate in a phase 1 trial and met its primary endpoint in the phase 2 QUINTESSENTIAL trial. As more patients become refractory to existing therapies, novel targets like GPRC5D could be key to pushing the field closer to a cure.
Beyond BCMA: A new CAR T-cell target is reshaping the myeloma treatment landscape
The multiple myeloma treatment landscape is evolving fast — and so is the need for new targets. As patients increasingly receive aggressive quadruplet regimens upfront, they're becoming resistant to multiple drug classes earlier than ever. That's creating a growing population of heavily pretreated patients who need something new, and GPRC5D-directed CAR T-cell therapy may be the answer.
Arlocabtagene autoleucel (arlo-cel), a GPRC5D-targeted CAR T-cell therapy, has shown impressive results in clinical trials. In a first-in-human phase 1 study, it demonstrated strong efficacy in relapsed/refractory myeloma, and the phase 2 QUINTESSENTIAL trial met its primary endpoint in patients who had received at least 4 prior lines of therapy.
By the Numbers
Why it matters: With BCMA-directed therapies moving into earlier treatment lines, patients are running out of options sooner. GPRC5D offers a distinct target that could extend meaningful responses — and potentially bring the field closer to a cure in multiple myeloma.
